Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

2.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.4K
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.1K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

370
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
370
Drug Regulation01:25

Drug Regulation

1.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.0K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.0K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

420
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
420

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ToxMet: a web tool for toxicogenomic data analysis using genome-scale metabolic modeling.

Toxicological sciences : an official journal of the Society of Toxicology·2026
Same author

Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development.

Therapeutic innovation & regulatory science·2026
Same author

Synapse specific alterations of autophagy are a hallmark of Danon disease.

bioRxiv : the preprint server for biology·2026
Same author

Distinct Metabolic Signatures Linked to High-Resolution Computed Tomography Radiographic Phenotypes in Stable and Progressive Fibrotic Lung Disease.

Metabolites·2026
Same author

Insights Informing Strategies for Optimizing the Collection of Clinical Trial Data.

Therapeutic innovation & regulatory science·2025
Same author

Astrocyte-specific deletion of ceruloplasmin exacerbates oxidative stress and demyelination in the spinal cord in a murine model of multiple sclerosis.

Neurobiology of disease·2025

Related Experiment Video

Updated: May 8, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.2K

Assessing the Value of Integrated Evidence Approaches in Drug Development.

Joseph A DiMasi1, Melvin Skip Olson2, Zachary Smith3

  • 1Tufts Center for the Study of Drug Development, Tufts University, 145 Harrison Avenue, Boston, MA, 02111, USA. joseph.dimasi@tufts.edu.

Therapeutic Innovation & Regulatory Science
|April 23, 2025
PubMed
Summary

Integrated Evidence Plans (IEPs) offer substantial value in pharmaceutical development by optimizing outcomes. Applying value drivers and expected net present value (eNPV) models quantifies this value, guiding project teams toward objective decision-making.

Keywords:
Clinical development phasesExpected net present valueIntegrated evidenceStrategic decision makingValue of evidence

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.0K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K

Related Experiment Videos

Last Updated: May 8, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.2K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.0K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K

Area of Science:

  • Pharmaceutical Development
  • Health Economics
  • Regulatory Science

Background:

  • Integrated Evidence Plans (IEPs) are increasingly used in pharma to enhance healthcare and patient outcomes.
  • IEPs utilize evidence beyond traditional trials for holistic, stakeholder-relevant data, adaptable to regional needs.
  • Sponsor adoption is limited by perceived uncertainty in the investment value of this drug development approach.

Purpose of the Study:

  • To introduce and apply value drivers within an expected net present value (eNPV) model to quantify the financial benefits of IEPs.
  • To assess the incremental value generated by employing Integrated Evidence Programs (IEPs) compared to traditional methods.
  • To provide a framework for objective economic analysis in pharmaceutical project planning.

Main Methods:

  • Developed an expected net present value (eNPV) model incorporating value drivers for drug development and commercialization cash flows.
  • Applied the eNPV model to two hypothetical lifecycle management IEP scenarios.
  • Defined IEP value as the increase in eNPV achieved through IE programs versus their absence.

Main Results:

  • IEPs demonstrated substantial value, with significant positive increments in eNPV observed in both hypothetical cases.
  • One scenario showed an observational study supporting approval in lieu of a Phase II trial for a supplemental indication.
  • Another scenario highlighted increased treatment adoption and positive eNPV from Phase IIIb study evidence.

Conclusions:

  • Value drivers and eNPV models offer objective guidance for IEP planning in pharmaceutical development.
  • Formal economic analysis, considering timelines, costs, regulatory approval likelihood, and market adoption, can estimate IEP value.
  • This approach supports informed decision-making for maximizing the return on investment in novel drug development strategies.